The advent of disease-modifying therapies (DMTs) has significantly altered the treatment of Alzheimer’s disease (AD), making timely and accurate diagnosis essential for optimal management. Detecting AD pathology with imaging and fluid biomarkers is critical for identifying patients eligible for these newer therapies. https://www.emedevents.com/online-cme-courses/webcasts/patientgps-in-alzheimer-s-disease-navigating-the-use-of-fluid-biomarker-testing-for-early-disease-identification-and-management-2